06,28-06

04)

- 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1				
1006 W	no persons are required		tent and Trade	PTO/SB/21 (0 d for use through 07/31/2006. OMB 0651-0031 emark Office; U.S. DEPARTMENT OF COMMI mation unless it displays a valid OMB control nu
(CE) INC.	to porconic are roquired	Application N		10/572,415
TRANSMITTAL		Filing Date		March 17, 2006
FORM	First Named	Inventor	Anders Hjelmencrantz	
		Art Unit		N/A
(to be used for all correspondence afte	er muai ming)	Examiner Na	me	Not Yet Assigned
Total Number of Pages in This Submis	sion	Attorney Docket Number 64921(45579)		64921(45579)
El	NCLOSURES	(Check all t	hat apply)
Fee Transmittal Form	Drawing(s)	·		After Allowance Communication to TC
Fee Attached	Licensing-rel	ated Papers		Appeal Communication to Board of Appeals and Interferences
Amendment/Reply Petition				Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
After Final Petition to Co				Proprietary Information
Affidavits/declaration(s)		rney, Revocation rrespondence A		Status Letter
Extension of Time Request Terminal I		claimer		X Other Enclosure(s) (please Identify below):
Express Abandonment Request	Request for	Refund		Form PTO/SB/08a/b (5 References) (1 page)
X Information Disclosure Statement	CD, Number of CD(s)		(Copies of 5 References Return Receipt Postcard
Certified Copy of Priority	Landsc	ape Table on C		vetum receipt r ostcaru
Document(s) Reply to Missing Parts/	Remarks			
Incomplete Application Reply to Missing Parts under				
37 CFR 1.52 or 1.53				
SIGNAT	URE OF APPLICA	NT, ATTORN	IEY, OR A	GENT
Firm Name EDWARDS ANGEL			,	
Signature Sydn	AA			
Printed name Stephana E. Patton			··-	
Date June 26, 2006		R	eg. No. 5	50,373



Docket No.: 64921(45579)

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Anders Hjelmencrantz et al.

Application No.: 10/572,415

Filed: March 17, 2006 Art Unit: N/A

For: BENZIMIDAZOLE DERIVATIVES AND

USE THEREOF AS PEPTIDE DEFORMYLASE INHIBITORS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications.

Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 64921(45579).

Dated: June 26, 2006

Respectfully submitted,

Stephana E. Patton

Registration No.: 50,373

EDWARDS ANGELL PALMER & DODGE

LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known			
				Application Number	10/572,415
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			SCLOSURE	Filing Date	March 17, 2006
			APPLICANT	First Named Inventor	Anders Hjelmencrantz
				Art Unit	N/A
			necessary)	Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	64921(45579)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁴ Applicant is to place a check mark here if English language

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	John Clements, et al., "Peptide Deformylase Inhibitors, Potential for a New Class of Broad Spectrum Antibacterials," Curr. Med. Chem. Anti-Infective Agents, (2002), 1, pp. 239-249.	
	СВ	Z. Yuan et al., "Deformylse as a novel antibacterial target," Drug Discovery Today, (2001), 6, (2001), pp. 954-961.	
	СС	C. Giglione et al., "Peptide deformylase as a target for new generation, broad spectrum antimircobial agents", Molecular Microbiology, (2002), 36, pp. 1197-1205.	
	CD	C. Giglione et al., "Peptide deformylase as an emerging target for antiparasitic agents", Emerging Therapeutic Targets, 5, (2001), pp. 41-57.	
	CE	Dehua Pei, "Peptide deformylase: a target for novel antibiotic?", Emerging Therapeutic Targets, 5, (2001), pp. 23-40.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date
Signature	Considered
551306	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

pplication No. (if known): 10/572,415


Attorney Docket No.: 64921(45579)

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 755075170 US in an envelope addressed to:

> MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

June 26, 2006 Date



Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal (1 page) Information Disclosure Statement (2 pages) IDS (Citation) by Applicant (5 References) (1 page) Copies of 5 References Return Receipt Postcard